BioProNET2 - Academic–Industry Network

Dear <<First Name>>,

BioProNET has evolved and returned as BioProNET2, an academic-industry networking club with sponsorship through a group of industrial and commercial colleagues who together with a group of academics (see below) aim to maintain and develop the community that was brought together so successfully by BioProNET. Our general objectives are to:

• mobilise a collaborative UK scientific community to address the challenges around, and enhance, the manufacture of emerging novel biological modalities.
• capitalise on entrepreneurship and address fundamental scientific challenges to enable robust and economically viable manufacture. 
• develop a forum to engage academics and early career researchers with the industrial sector and entrepreneurial practitioners to provide a framework to train and inspire the next generation.

As a starting point for the focus of BioProNET2 we will be running an annual scientific meeting and a series of subject-specific workshops throughout each year, which this year will have a virtual, on-line structure. You have previously been associated with, and/or attended, meetings organised by BioProNET and, at this stage, we wish to inform you of our general plans and ask you to indicate your interest in hearing about, and being involved in, future activities organised by BioProNET2. We hope that you will and would ask you to forward this communication to any colleagues who you would also think would be interested in being part of BioProNET2 activities.
 

Just insert the appropriate heading and return this e-mail to the sending address:

YES, please!! Let me know all about BioProNET2 activities
NO, thank you, this is no longer appropriate for me

We are currently updating our BioProNET2 website so please check HERE and our Twitter feed for further information.
 

BioProNET2 Steering Group:

Paul Dalby (UCL), Alan Dickson (University of Manchester), Jo Flannelly (University of Manchester), Cleo Kontoravdi (Imperial College), Mark Smales (University of Kent), Ivan Wall (Aston University).

Current industrialists include representatives of Allergan Biologics, AZ, Cell & Gene Therapy Catapult, Cobra Biologics, Fujifilm Diosynth Biotechnologies, GSK, Kymab, Lonza Biologics, Pall Corporation.